Trials / Completed
CompletedNCT02013687
Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study is a Phase 1, dose escalation, first-in-human study designed primarily to evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel adjuvant
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pfs25 VLP- FhCMB |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-08-01
- Completion
- 2015-01-01
- First posted
- 2013-12-17
- Last updated
- 2017-03-08
- Results posted
- 2017-01-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02013687. Inclusion in this directory is not an endorsement.